Analyst Ratings For Conatus Pharmaceuticals (NASDAQ:CNAT)
Today, Stifel Nicolaus reiterated its Buy rating on Conatus Pharmaceuticals (NASDAQ:CNAT) with a price target of $10.00.
There are 7 buy ratings on the stock.
The current consensus rating on Conatus Pharmaceuticals (NASDAQ:CNAT) is Buy (Score: 3.00) with a consensus target price of $14.67 per share, a potential 192.16% upside.
Some recent analyst ratings include
- 8/3/2017-Stifel Nicolaus Reiterated Rating of Buy.
- 6/29/2017-HC Wainwright Reiterated Rating of Buy.
- 5/15/2017-Aegis Reiterated Rating of Buy.
- 3/15/2017-FBR & Co Reiterated Rating of Outperform.
- 12/23/2016-SunTrust Banks, Inc. Reiterated Rating of Buy.
- 11/9/2016-JMP Securities Reiterated Rating of Buy.
- 10/4/2016-Brean Capital Reiterated Rating of Buy.
Recent Insider Trading Activity For Conatus Pharmaceuticals (NASDAQ:CNAT)
Conatus Pharmaceuticals (NASDAQ:CNAT) has insider ownership of 13.90% and institutional ownership of 22.34%.
- On 4/8/2015 Daniel L Kisner, Director, bought 4,000 with an average share price of $5.75 per share and the total transaction amounting to $23,000.00. View SEC Filing
- On 7/30/2013 David F Hale, Director, bought 2,588 with an average share price of $11.00 per share and the total transaction amounting to $28,468.00. View SEC Filing
- On 7/30/2013 Luke Evnin, Major Shareholder, bought 165,265 with an average share price of $11.00 per share and the total transaction amounting to $1,817,915.00. View SEC Filing
- On 7/30/2013 Steven J Mento, CEO, bought 13,800 with an average share price of $11.00 per share and the total transaction amounting to $151,800.00. View SEC Filing
Recent Trading Activity for Conatus Pharmaceuticals (NASDAQ:CNAT)
Shares of Conatus Pharmaceuticals closed the previous trading session at 5.02 down -0.42 -7.72% with 344,448 shares trading hands.